WVU plans for phased return to campuses for fall 2020 semester. Visit Return to Campus: Health Sciences for information. Visit coronavirus.wvu.edu for the latest regarding COVID-19.

Clinical Research

Clinical trials play a large and growing role in the medical options patients have today and in the future.  Nearly 4,000 experimental drug therapies are in active clinical trials today and that number will continue to grow as improvements are made in detecting disease, in understanding the root causes of acute and chronic illnesses, and in discovering medical innovations.

Clinical trials help to establish therapeutic innovations for vision threatening diseases. By participating with informed consent in clinical trials at the WVU Eye Institute, patients can receive new treatments before they become widely available to the public. In addition, because certain vision threatening diseases such as glaucoma tends to run in families, participating in clinical trials may one day benefit the children and grandchildren of participants.

The WVU Eye Institute clinical research program is directed by Tony Realini, MD, MPH.

To find out if you are eligible to participate in a clinical trial – contact Aimie Jones at jonesai@wvumedicine.org.

Clinical trials research opportunities include:

  • Dr. Ghassan Ghorayeb - MYL-1701P-3001  : Comparative Study of Evaluate the Efficacy and Safety of MyL-1701P and Eylea in subjects with Diabetic Macular Edema - Open to Enrollment
  • Dr. Ghassan Ghorayeb - GR43049: Study to Evaluate the Efficacy and Safety of RO6867461 in patients with Diabetic Macular Edema - Closed to Enrollment
  • Dr. Ghassan Ghorayeb - Pending: Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in patients with Diabetic Macular Edema
  • Dr. Ghassan Ghorayeb - KHB-1801: Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injections in subjects with Neovascular Age-related Macular Degeneration - Closed to Enrollment
  • Dr. Ghassan Ghorayeb - GTSCOPE : Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy Secondary to Age Related Macular Degeneration - Open to Enrollment
  • Dr. Ghassan Ghorayeb - CRTH258B2305 : Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment Due to Diabetic Macular Edema - Closed to Enrollment
  • Dr. Ghassan Ghorayeb - CRTH258A2303: Phase IIIb Study Assessing the Efficacy and Safety Brolucizumab 6mg compared to Aflibercept 2 mg in a Treat-To-Control Regimen in Patients with Neovascular Age-Related Macular Degeneration - Open to Enrollment
  • Dr. Ghassan Ghorayeb - VGFTe-ROP-1920: Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity - Open to Enrollment
  • Dr. Ghassan Ghorayeb - VGFTe(HD)-AMD-1905: Phase II Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration - Open to Enrollment
  • Dr. Ghassan Ghorayeb - Pending: Phase III Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
  • Dr. Ghassan Ghorayeb - Pending: Phase 2/3 Study of Efficacy and Safety of High Dose Aflibercept in Patients with Diabetic Macular Edema
  • Dr. Ghassan Ghorayeb - Pending: Phase III Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to a Central Retinal Vein Occlusion
  • Dr. Ghassan Ghorayeb - Pending: Phase 2 Study to Asses the Dose Level of Multiple THR-149 Injections and to Evaluate the Efficacy and Safety of THR-149 versus Aflibercept for the Treatment of Diabetic Macular Edema
  • Dr. David Hinkle -  010906IN LUMINA: Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 uf DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye - Open to Enrollment
  • Dr. Geoffrey Bradford - 081CTXX15001: Study of the Prevalence of Cerebrotendinous Xanthomastosis (CTX) in Patient Population Diagnosis with Early Onset Idiopathic Bilateral Cataracts - Open to Enrollment
  • Dr. Lingo Lai - Phase II Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects - Open to Enrollment
  • Dr. Monique Leys - My Retina Tracker Registry; My Retina Track Genetic Testing Protocol - Open to Enrollment
  • Dr. Brian McMillan - 192024-093: Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension - Open to Enrollment
  • Dr. John Nguyen - ASCEND GO 2: Phase IIb Studyfor the Treatment of Patients with Active, Moderate to Severe Graves' Ophthalmopathy (GO) - Open to Enrollment 

Learn more about clinical trials in vision research here